Our representatives located in Japan, China, Singapore and Indiaare dedicated to providing customers with on-site support and solutions unique to their processes based on our expertise in virus removal filtration and bioprocessing.
Audit reports for Planova manufacturing facilities are now available for purchase from Rx-360, an international pharmaceutical supply chain consortium. Please follow the links below to purchase the reports.
• Audit Report for Planova Plant (located in Nobeoka-shi, Miyazaki, Japan):
• Audit Report for Planova Oita Plant (located in Oita-shi, Oita, Japan):
We recently renewed our laboratory at the Planova™ R&D center in Nobeoka, Japan for conducting virus studies on Planova™ filters. Filter performance is analyzed using porcine parvovirus (PPV).
With over 20 years of virus filtration experience, our virus laboratory scientists in Nobeoka are available to support customers with virus clearance consultancy services.
As a part of our customer support services, we offer non-GLP virus studies on customer protein solution samples.
We can optimize filtration conditions and develop virus filtration process designs. We offer preliminary testing and virus-spiking filtration studies.
Using samples from the planned process feed, our technical team will conduct non-GLP virus studies using stock virus developed by Asahi Kasei Bioprocess. Conducting these studies before the actual GLP virus validation effectively reduces the risk of failure in GLP studies.
Using virus solutions with low purity or low titer hinders study outcomes due to filter clogging or insufficient log reduction value (LRV). We use a unique PPV stock that is serum-free and has a high titer.
Please compare our method for high titer, serum-free PPV stock production with the conventional method.
Our PPV stock preparation method minimizes impurities derived from serum and yields a high titer (>8 log) virus stock without aggregation of virus particles. Using this stock in virus studies has the following merits: